{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T21:40:09Z","timestamp":1751492409549,"version":"3.41.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,2]]},"DOI":"10.7759\/cureus.87183","type":"journal-article","created":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T20:59:46Z","timestamp":1751489986000},"source":"Crossref","is-referenced-by-count":0,"title":["Outcomes in Patients With Multiple Myeloma and Prescribed Urate-Lowering Therapy: A Propensity-Matched Study"],"prefix":"10.7759","author":[{"given":"Sarah","family":"Eidbo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maxim","family":"Barnett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diego","family":"Lema Rodriguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nanuka","family":"Tsibadze","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Pappas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohibur","family":"Shah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abhishek","family":"Shah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryan","family":"Mayo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2021.103504","article-title":"Efficacy of first-line treatment options in transplant-ineligible multiple myeloma: a network meta-analysis","volume":"168","author":"Kiss S","year":"2021","unstructured":"Kiss S, Gede N, So\u00f3s A, et al.. Efficacy of first-line treatment options in transplant-ineligible multiple myeloma: a network meta-analysis. Crit Rev Oncol Hematol. 2021, 168:103504. 10.1016\/j.critrevonc.2021.103504","journal-title":"Crit Rev Oncol Hematol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/S1040-8428(01)00102-0","article-title":"Cancer epidemiology in the elderly","volume":"39","author":"Franceschi S","year":"2001","unstructured":"Franceschi S, La Vecchia C. Cancer epidemiology in the elderly. Crit Rev Oncol Hematol. 2001, 39:219-26. 10.1016\/S1040-8428(01)00102-0","journal-title":"Crit Rev Oncol Hematol"},{"key":"ref3","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2018.206912","article-title":"Efficacy of first-line treatments for multiple myeloma patients not eligible for stem cell transplantation: a network meta-analysis","volume":"104","author":"Blommestein HM","year":"2019","unstructured":"Blommestein HM, van Beurden-Tan CH, Franken MG, Uyl-de Groot CA, Sonneveld P, Zweegman S. Efficacy of first-line treatments for multiple myeloma patients not eligible for stem cell transplantation: a network meta-analysis. Haematologica. 2019, 104:1026-35.","journal-title":"Haematologica"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)60493-1","article-title":"Multiple myeloma","volume":"385","author":"R\u00f6llig C","year":"2015","unstructured":"R\u00f6llig C, Knop S, Bornh\u00e4user M. Multiple myeloma. Lancet. 2015, 385:2197-208. 10.1016\/S0140-6736(14)60493-1","journal-title":"Lancet"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709974","article-title":"Long-term follow-up of monoclonal gammopathy of undetermined significance","volume":"378","author":"Kyle RA","year":"2018","unstructured":"Kyle RA, Larson DR, Therneau TM, Dispenzieri A, Kumar S, Cerhan JR, Rajkumar SV. Long-term follow-up of monoclonal gammopathy of undetermined significance. N Engl J Med. 2018, 378:241-9. 10.1056\/NEJMoa1709974","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(78)90522-3","article-title":"Monoclonal gammopathy of undetermined significance. Natural history in 241 cases","volume":"64","author":"Kyle R","year":"1978","unstructured":"Kyle R. Monoclonal gammopathy of undetermined significance. Natural history in 241 cases. Am J Med. 1978, 64:814-26. 10.1016\/0002-9343(78)90522-3","journal-title":"Am J Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-09-692954","article-title":"MGUS to myeloma: a mysterious gammopathy of underexplored significance","volume":"128","author":"Dhodapkar MV","year":"2016","unstructured":"Dhodapkar MV. MGUS to myeloma: a mysterious gammopathy of underexplored significance. Blood. 2016, 128:2599-606. 10.1182\/blood-2016-09-692954","journal-title":"Blood"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.4137\/CGM.S16817","article-title":"Bone disease in multiple myeloma: pathophysiology and management","volume":"7","author":"Hameed A","year":"2014","unstructured":"Hameed A, Brady JJ, Dowling P, Clynes M, O'Gorman P. Bone disease in multiple myeloma: pathophysiology and management. Cancer Growth Metastasis. 2014, 7:33-42. 10.4137\/CGM.S16817","journal-title":"Cancer Growth Metastasis"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1989.7.12.1909","article-title":"Mechanisms of bone destruction in multiple myeloma: the importance of an unbalanced process in determining the severity of lytic bone disease","volume":"7","author":"Bataille R","year":"1989","unstructured":"Bataille R, Chappard D, Marcelli C, Dessauw P, Sany J, Baldet P, Alexandre C. Mechanisms of bone destruction in multiple myeloma: the importance of an unbalanced process in determining the severity of lytic bone disease. J Clin Oncol. 1989, 7:1909-14. 10.1200\/JCO.1989.7.12.1909","journal-title":"J Clin Oncol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25791","article-title":"Multiple myeloma: 2020 update on diagnosis, risk-stratification and management","volume":"95","author":"Rajkumar SV","year":"2020","unstructured":"Rajkumar SV. Multiple myeloma: 2020 update on diagnosis, risk-stratification and management. Am J Hematol. 2020, 95:548-67. 10.1002\/ajh.25791","journal-title":"Am J Hematol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.30.8791","article-title":"Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group","volume":"28","author":"Dimopoulos MA","year":"2010","unstructured":"Dimopoulos MA, Terpos E, Chanan-Khan A, et al.. Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group. J Clin Oncol. 2010, 28:4976-84. 10.1200\/JCO.2010.30.8791","journal-title":"J Clin Oncol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/s1092-9134(00)90042-x","article-title":"Renal manifestations of plasma cell dyscrasias: an appraisal from the patients' bedside to the research laboratory","volume":"4","author":"Herreira GA","year":"2000","unstructured":"Herreira GA. Renal manifestations of plasma cell dyscrasias: an appraisal from the patients' bedside to the research laboratory. Ann Diagn Pathol. 2000, 4:174-200. 10.1016\/s1092-9134(00)90042-x","journal-title":"Ann Diagn Pathol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdi235","article-title":"Myeloma bone disease: pathophysiology and management","volume":"16","author":"Terpos E","year":"2005","unstructured":"Terpos E, Dimopoulos MA. Myeloma bone disease: pathophysiology and management. Ann Oncol. 2005, 16:1223-31. 10.1093\/annonc\/mdi235","journal-title":"Ann Oncol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2004.05094.x","article-title":"Tumour lysis syndrome: new therapeutic strategies and classification","volume":"127","author":"Cairo MS","year":"2004","unstructured":"Cairo MS, Bishop M. Tumour lysis syndrome: new therapeutic strategies and classification. Br J Haematol. 2004, 127:3-11. 10.1111\/j.1365-2141.2004.05094.x","journal-title":"Br J Haematol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13403","article-title":"Guidelines for the management of tumour lysis syndrome in adults and children with haematological malignancies on behalf of the British Committee for Standards in Haematology","volume":"169","author":"Jones GL","year":"2015","unstructured":"Jones GL, Will A, Jackson GH, Webb NJ, Rule S. Guidelines for the management of tumour lysis syndrome in adults and children with haematological malignancies on behalf of the British Committee for Standards in Haematology. Br J Haematol. 2015, 169:661-71. 10.1111\/bjh.13403","journal-title":"Br J Haematol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.3816\/SCT.2005.n.008","article-title":"Optimizing management of tumor lysis syndrome in adults with hematologic malignancies","volume":"2","author":"Michallet AS","year":"2005","unstructured":"Michallet AS, Tartas S, Coiffier B. Optimizing management of tumor lysis syndrome in adults with hematologic malignancies. Support Cancer Ther. 2005, 2:159-66. 10.3816\/SCT.2005.n.008","journal-title":"Support Cancer Ther"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.15.0177","article-title":"Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review","volume":"26","author":"Coiffier B","year":"2008","unstructured":"Coiffier B, Altman A, Pui CH, Younes A, Cairo MS. Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review. J Clin Oncol. 2008, 26:2767-78. 10.1200\/JCO.2007.15.0177","journal-title":"J Clin Oncol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2011.09.011","article-title":"Increased risk of cancer among gout patients: a nationwide population study","volume":"79","author":"Kuo CF","year":"2012","unstructured":"Kuo CF, Luo SF, See LC, Chou IJ, Fang YF, Yu KH. Increased risk of cancer among gout patients: a nationwide population study. Joint Bone Spine. 2012, 79:375-8. 10.1016\/j.jbspin.2011.09.011","journal-title":"Joint Bone Spine"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.5114\/aoms\/161285","article-title":"Seronegative rheumatoid arthritis as the first manifestation of multiple myeloma-associated amyloid arthropathy","volume":"19","author":"Wang G","year":"2023","unstructured":"Wang G, Zhuo N, Tang M, Xue L, Liu Z. Seronegative rheumatoid arthritis as the first manifestation of multiple myeloma-associated amyloid arthropathy. Arch Med Sci. 2023, 19:539-41. 10.5114\/aoms\/161285","journal-title":"Arch Med Sci"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2020.02.002","article-title":"Residual urine output and mortality in a prospective hemodialysis cohort","volume":"5","author":"You AS","year":"2020","unstructured":"You AS, Kalantar-Zadeh K, Obi Y, et al.. Residual urine output and mortality in a prospective hemodialysis cohort. Kidney Int Rep. 2020, 5:643-53. 10.1016\/j.ekir.2020.02.002","journal-title":"Kidney Int Rep"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpcardiol.2022.101437","article-title":"The burden of cardiac arrhythmias in gout: a national representative database study","volume":"48","author":"Mhanna M","year":"2023","unstructured":"Mhanna M, Jabri A, Omar YA, et al.. The burden of cardiac arrhythmias in gout: a national representative database study. Curr Probl Cardiol. 2023, 48:101437. 10.1016\/j.cpcardiol.2022.101437","journal-title":"Curr Probl Cardiol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv317","article-title":"FLORENCE: a randomized, double-blind, phase III pivotal study of febuxostat versus allopurinol for the prevention of tumor lysis syndrome (TLS) in patients with hematologic malignancies at intermediate to high TLS risk","volume":"26","author":"Spina M","year":"2015","unstructured":"Spina M, Nagy Z, Ribera JM, et al.. FLORENCE: a randomized, double-blind, phase III pivotal study of febuxostat versus allopurinol for the prevention of tumor lysis syndrome (TLS) in patients with hematologic malignancies at intermediate to high TLS risk. Ann Oncol. 2015, 26:2155-61. 10.1093\/annonc\/mdv317","journal-title":"Ann Oncol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1517\/17425255.2014.904285","article-title":"Febuxostat: drug review and update","volume":"10","author":"Grewal HK","year":"2014","unstructured":"Grewal HK, Martinez JR, Espinoza LR. Febuxostat: drug review and update. Expert Opin Drug Metab Toxicol. 2014, 10:747-58. 10.1517\/17425255.2014.904285","journal-title":"Expert Opin Drug Metab Toxicol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/380945-outcomes-in-patients-with-multiple-myeloma-and-prescribed-urate-lowering-therapy-a-propensity-matched-study","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T20:59:47Z","timestamp":1751489987000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/380945-outcomes-in-patients-with-multiple-myeloma-and-prescribed-urate-lowering-therapy-a-propensity-matched-study"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,2]]},"references-count":23,"URL":"https:\/\/doi.org\/10.7759\/cureus.87183","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7,2]]}}}